Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI117890

Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia.

A Arnold, M F Brown, P Ureña, R D Gaz, E Sarfati, and T B Drüeke

Laboratory of Endocrine Oncology, Massachusetts General Hospital, Boston 02114, USA.

Find articles by Arnold, A. in: PubMed | Google Scholar

Laboratory of Endocrine Oncology, Massachusetts General Hospital, Boston 02114, USA.

Find articles by Brown, M. in: PubMed | Google Scholar

Laboratory of Endocrine Oncology, Massachusetts General Hospital, Boston 02114, USA.

Find articles by Ureña, P. in: PubMed | Google Scholar

Laboratory of Endocrine Oncology, Massachusetts General Hospital, Boston 02114, USA.

Find articles by Gaz, R. in: PubMed | Google Scholar

Laboratory of Endocrine Oncology, Massachusetts General Hospital, Boston 02114, USA.

Find articles by Sarfati, E. in: PubMed | Google Scholar

Laboratory of Endocrine Oncology, Massachusetts General Hospital, Boston 02114, USA.

Find articles by Drüeke, T. in: PubMed | Google Scholar

Published May 1, 1995 - More info

Published in Volume 95, Issue 5 on May 1, 1995
J Clin Invest. 1995;95(5):2047–2053. https://doi.org/10.1172/JCI117890.
© 1995 The American Society for Clinical Investigation
Published May 1, 1995 - Version history
View PDF
Abstract

The pathogeneses of parathyroid disease in patients with uremia and nonfamilial primary parathyroid hyperplasia are poorly understood. Because of multigland involvement, it has been assumed that these common diseases predominantly involve polyclonal (non-neoplastic) cellular proliferations, but an overall assessment of their clonality has not been done. We examined the clonality of these hyperplastic parathyroid tumors using X-chromosome inactivation analysis with the M27 beta (DXS255) DNA polymorphism and by searching for monoclonal allelic losses at M27 beta and at loci on chromosome band 11q13. Fully 7 of 11 informative hemodialysis patients (64%) with uremic refractory hyperparathyroidism harbored at least one monoclonal parathyroid tumor (with a minimum of 12 of their 19 available glands being monoclonal). Tumor monoclonality was demonstrable in 6 of 16 informative patients (38%) with primary parathyroid hyperplasia. Histopathologic categories of nodular versus generalized hyperplasia were not useful predictors of clonal status. These observations indicate that monoclonal parathyroid neoplasms are common in patients with uremic refractory hyperparathyroidism and also develop in a substantial group of patients with sporadic primary parathyroid hyperplasia, thereby changing our concept of the pathogenesis of these diseases. Neoplastic transformation of preexisting polyclonal hyperplasia, apparently due in large part to genes not yet implicated in parathyroid tumorigenesis and possibly including a novel X-chromosome tumor suppressor gene, is likely to play a central role in these disorders.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 2047
page 2047
icon of scanned page 2048
page 2048
icon of scanned page 2049
page 2049
icon of scanned page 2050
page 2050
icon of scanned page 2051
page 2051
icon of scanned page 2052
page 2052
icon of scanned page 2053
page 2053
Version history
  • Version 1 (May 1, 1995): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts